<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04068051</url>
  </required_header>
  <id_info>
    <org_study_id>AXS-07-302</org_study_id>
    <nct_id>NCT04068051</nct_id>
  </id_info>
  <brief_title>Open-Label Long-Term Safety Study of AXS-07 for the Acute Treatment of Migraine</brief_title>
  <official_title>An Open-Label, Long-Term Study to Assess the Safety and Efficacy of AXS-07 (MoSEIC Meloxicam and Rizatriptan) for the Acute Treatment of Migraine in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Axsome Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Axsome Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to evaluate the long-term safety of chronic intermittent use of AXS-07 and to assess
      the effect of AXS-07 on migraine symptoms following repeated treatment of migraine attacks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase 3, multicenter, open-label, trial to evaluate the long-term safety and
      efficacy of intermittent chronic dosing with AXS-07 in subjects with migraine attacks.
      Eligible subjects will take AXS-07 following the onset of a migraine. Subjects will be
      treated for up to 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2019</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events</measure>
    <time_frame>Following dosing with AXS-07 over the course of up to one year</time_frame>
    <description>Safety</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with headache pain freedom</measure>
    <time_frame>Hour 2 following dose administration</time_frame>
    <description>Absence of headache pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with absence of the most bothersome symptom</measure>
    <time_frame>Hour 2 following dose administration</time_frame>
    <description>Absence of most bothersome symptom, defined at the onset of migraine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with headache pain relief</measure>
    <time_frame>Hour 2 following dose administration</time_frame>
    <description>Mild or no headache pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects reporting sustained headache pain freedom</measure>
    <time_frame>Hours 2 through 24 following dose administration</time_frame>
    <description>Sustained headache pain freedom without use of rescue medication and no relapse of headache pain</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>AXS-07</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AXS-07</intervention_name>
    <description>AXS-07 (MoSEIC meloxicam and rizatriptan) taken by mouth for the acute treatment of migraine.</description>
    <arm_group_label>AXS-07</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has participated in a prior study with AXS-07 for the treatment of migraine

        Exclusion Criteria:

          -  Has previously received any investigational drug or device or investigational therapy
             within 30 days before Screening, other than AXS-07

          -  Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Director</last_name>
    <phone>2123323241</phone>
    <email>ajones@axsome.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 27, 2019</study_first_submitted>
  <study_first_submitted_qc>August 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>August 22, 2019</last_update_submitted>
  <last_update_submitted_qc>August 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Axsome</keyword>
  <keyword>AXS-07</keyword>
  <keyword>MoSEIC meloxicam</keyword>
  <keyword>rizatriptan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

